Efficacy and Safety of Extended TARPEYO Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
RECRUITING
Worldwide Clinical Trials
PHASE4
2024-12-17
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is:
Is there a treatment benefit of TARPEYO 16 mg QD extended use?
Participants will
* take part in this study for about 19 months
* Have urine tests done
* Have blood samples taken
* Have physical examinations done
Efficacy and Safety of Extended TARPEYO Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
RECRUITING
Calliditas Therapeutics AB
PHASE4
2024-12-17
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is:
Is there a treatment benefit of TARPEYO 16 mg QD extended use?
Participants will
* take part in this study for about 19 months
* Have urine tests done
* Have blood samples taken
* Have physical examinations done
Relative Bioavailability Study of HR19042 in Healthy Subjects
COMPLETED
Jiangsu HengRui Medicine Co., Ltd.
PHASE1
2023-12-27
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study.
Primary Objective
1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release capsules (Tarpeyo) and budesonide enteric-coated capsules (Budenofalk).
Secondary Objective
2. To assess safety following administration.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
